Advanced search
Add to list

Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy

(2011) INFLAMMATORY BOWEL DISEASES. 17(9). p.1846-1854
Author
Organization
Abstract
Background: Infliximab (IFX) and adalimumab (ADA) are attractive treatment options in patients with inflammatory bowel disease (IBD) also during pregnancy but there is still limited data on the benefit/risk profile of IFX and ADA during pregnancy. Methods: This observational study assessed pregnancy outcomes in 212 women with IBD under antitumor necrosis factor alpha (TNF) treatment at our IBD unit. Pregnancy outcomes in 42 pregnancies with direct exposure to anti-TNF treatment (35 IFX, 7 ADA) were compared with that in 23 pregnancies prior to IBD diagnosis, 78 pregnancies before start of IFX, 53 pregnancies with indirect exposure to IFX, and 56 matched pregnancies in healthy women. Results: Thirty-two of the 42 pregnancies ended in live births with a median gestational age of 38 weeks (interquartile range PORI 37-39). There were seven premature deliveries, six children had low birth weight, and there was one stillbirth. One boy weighed 1640 g delivered at week 33, died at age of 13 days because of necrotizing enterocolitis. A total of eight abortions (one patient wish) occurred in seven women. Trisomy 18 was diagnosed in one fetus of a mother with CD at age 37 under ADA treatment (40 mg weekly) and pregnancy was terminated. Pregnancy outcomes after direct exposure to anti-TNF treatment were not different from those in pregnancies before anti-TNF treatment or with indirect exposure to anti-TNF treatment but outcomes were worse than in pregnancies before IBD diagnosis. Conclusions: Direct exposure to anti-TNF treatment during pregnancy was not related to a higher incidence of adverse pregnancy outcomes than IBD overall.
Keywords
inflammatory bowel disease, anti-TNF treatment, pregnancy outcome, intentional treatment, direct exposure to anti-TNF, CROHNS-DISEASE, INFLIXIMAB, MAINTENANCE, ADALIMUMAB, INDUCTION

Citation

Please use this url to cite or link to this publication:

MLA
Schnitzler, F., et al. “Outcome of Pregnancy in Women with Inflammatory Bowel Disease Treated with Antitumor Necrosis Factor Therapy.” INFLAMMATORY BOWEL DISEASES, vol. 17, no. 9, 2011, pp. 1846–54.
APA
Schnitzler, F., Fidder, H., Ferrante, M., Ballet, V., Noman, M., Van Assche, G., … Rutgeerts, P. (2011). Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. INFLAMMATORY BOWEL DISEASES, 17(9), 1846–1854.
Chicago author-date
Schnitzler, F, H Fidder, M Ferrante, V Ballet, M Noman, G Van Assche, B Spitz, et al. 2011. “Outcome of Pregnancy in Women with Inflammatory Bowel Disease Treated with Antitumor Necrosis Factor Therapy.” INFLAMMATORY BOWEL DISEASES 17 (9): 1846–54.
Chicago author-date (all authors)
Schnitzler, F, H Fidder, M Ferrante, V Ballet, M Noman, G Van Assche, B Spitz, I Hoffman, Kristel Van Steen, S Vermeire, and P Rutgeerts. 2011. “Outcome of Pregnancy in Women with Inflammatory Bowel Disease Treated with Antitumor Necrosis Factor Therapy.” INFLAMMATORY BOWEL DISEASES 17 (9): 1846–1854.
Vancouver
1.
Schnitzler F, Fidder H, Ferrante M, Ballet V, Noman M, Van Assche G, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. INFLAMMATORY BOWEL DISEASES. 2011;17(9):1846–54.
IEEE
[1]
F. Schnitzler et al., “Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy,” INFLAMMATORY BOWEL DISEASES, vol. 17, no. 9, pp. 1846–1854, 2011.
@article{5906723,
  abstract     = {Background: Infliximab (IFX) and adalimumab (ADA) are attractive treatment options in patients with inflammatory bowel disease (IBD) also during pregnancy but there is still limited data on the benefit/risk profile of IFX and ADA during pregnancy. 
Methods: This observational study assessed pregnancy outcomes in 212 women with IBD under antitumor necrosis factor alpha (TNF) treatment at our IBD unit. Pregnancy outcomes in 42 pregnancies with direct exposure to anti-TNF treatment (35 IFX, 7 ADA) were compared with that in 23 pregnancies prior to IBD diagnosis, 78 pregnancies before start of IFX, 53 pregnancies with indirect exposure to IFX, and 56 matched pregnancies in healthy women. 
Results: Thirty-two of the 42 pregnancies ended in live births with a median gestational age of 38 weeks (interquartile range PORI 37-39). There were seven premature deliveries, six children had low birth weight, and there was one stillbirth. One boy weighed 1640 g delivered at week 33, died at age of 13 days because of necrotizing enterocolitis. A total of eight abortions (one patient wish) occurred in seven women. Trisomy 18 was diagnosed in one fetus of a mother with CD at age 37 under ADA treatment (40 mg weekly) and pregnancy was terminated. Pregnancy outcomes after direct exposure to anti-TNF treatment were not different from those in pregnancies before anti-TNF treatment or with indirect exposure to anti-TNF treatment but outcomes were worse than in pregnancies before IBD diagnosis. 
Conclusions: Direct exposure to anti-TNF treatment during pregnancy was not related to a higher incidence of adverse pregnancy outcomes than IBD overall.},
  author       = {Schnitzler, F and Fidder, H and Ferrante, M and Ballet, V and Noman, M and Van Assche, G and Spitz, B and Hoffman, I and Van Steen, Kristel and Vermeire, S and Rutgeerts, P},
  issn         = {1078-0998},
  journal      = {INFLAMMATORY BOWEL DISEASES},
  keywords     = {inflammatory bowel disease,anti-TNF treatment,pregnancy outcome,intentional treatment,direct exposure to anti-TNF,CROHNS-DISEASE,INFLIXIMAB,MAINTENANCE,ADALIMUMAB,INDUCTION},
  language     = {eng},
  number       = {9},
  pages        = {1846--1854},
  title        = {Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy},
  url          = {http://dx.doi.org/10.1002/ibd.21583},
  volume       = {17},
  year         = {2011},
}

Altmetric
View in Altmetric
Web of Science
Times cited: